Literature DB >> 15856030

Oncogenic Ras increases sensitivity of colon cancer cells to 5-FU-induced apoptosis.

Lidija Klampfer1, Laurie-Anne Swaby, Jie Huang, Takehiko Sasazuki, Senji Shirasawa, Leonard Augenlicht.   

Abstract

Despite the fact that objective response rates to 5-FU are as low as 20%, 5-FU remains the most commonly used drug for the treatment of colorectal cancer. The lack of understanding of resistance to 5-FU, therefore, remains a significant impediment in maximizing its efficacy. We used intestinal epithelial cells with an inducible K-RasV12 to demonstrate that expression of oncogenic Ras promotes cell death upon 5-FU treatment. Accordingly, transient expression of the mutant RasV12, but not the WT Ras, enhanced 5-FU-induced apoptosis in 293T cells. Consistent with these data, we showed that targeted deletion of the mutant Ras allele in the HCT116 colon cancer cell line protected cells from 5-FU-induced apoptosis. Using isogenic colon cancer cell lines that differ only by the presence of the mutant Ras allele, HCT116 and Hke-3 cells, we demonstrated that signaling by oncogenic Ras promotes both accumulation of p53 and its phosphorylation on serine15 in response to 5-FU, a situation that favors apoptosis over growth arrest. However, despite the differential induction of p53 in HCT116 and Hke-3 cells, the expression of Puma, a gene with an important role in p53-dependent apoptosis, was not affected by Ras signaling. In contrast, we showed that Ras interferes with 5-FU-induced expression of gelsolin, a protein with known antiapoptotic activity. We ascertained the role of gelsolin in 5-FU-induced apoptosis by demonstrating that silencing of gelsolin expression through RNAi sensitized cells to 5-FU-induced apoptosis and that re-expression of gelsolin in cells harboring mutant Ras protected cells from 5-FU-induced apoptosis. These data therefore demonstrate that Ras mutations increase sensitivity to 5-FU-induced apoptosis at least in part through the negative regulation of gelsolin expression. Our data indicate that Ras mutations promote apoptosis in response to 5-FU treatment and imply that tumors with Ras mutations and/or reduced expression of gelsolin may show enhanced apoptosis in response to 5-FU also in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15856030     DOI: 10.1038/sj.onc.1208552

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  16 in total

1.  Activation of sterile20-like kinase 1 in proteasome inhibitor bortezomib-induced apoptosis in oncogenic K-ras-transformed cells.

Authors:  Fuminori Teraishi; Wei Guo; Lidong Zhang; Fengqing Dong; John J Davis; Takehiko Sasazuki; Senji Shirasawa; Jinsong Liu; Bingliang Fang
Journal:  Cancer Res       Date:  2006-06-15       Impact factor: 12.701

Review 2.  Regulation of homeostasis and oncogenesis in the intestinal epithelium by Ras.

Authors:  Sergia Velho; Kevin M Haigis
Journal:  Exp Cell Res       Date:  2011-06-17       Impact factor: 3.905

3.  Single-cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts.

Authors:  Rita Fior; Vanda Póvoa; Raquel V Mendes; Tânia Carvalho; António Gomes; Nuno Figueiredo; Miguel Godinho Ferreira
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-23       Impact factor: 11.205

4.  Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT.

Authors:  M Di Bartolomeo; F Pietrantonio; F Perrone; K F Dotti; A Lampis; C Bertan; E Beretta; L Rimassa; C Carbone; P Biondani; R Passalacqua; S Pilotti; E Bajetta
Journal:  Target Oncol       Date:  2013-07-03       Impact factor: 4.493

5.  Protein kinase C delta is required for survival of cells expressing activated p21RAS.

Authors:  Shuhua Xia; Lora W Forman; Douglas V Faller
Journal:  J Biol Chem       Date:  2007-03-08       Impact factor: 5.157

6.  Piper betle leaf extract enhances the cytotoxicity effect of 5-fluorouracil in inhibiting the growth of HT29 and HCT116 colon cancer cells.

Authors:  Pek Leng Ng; Nor Fadilah Rajab; Sue Mian Then; Yasmin Anum Mohd Yusof; Wan Zurinah Wan Ngah; Kar Yong Pin; Mee Lee Looi
Journal:  J Zhejiang Univ Sci B       Date:  2014-08       Impact factor: 3.066

7.  Activated kRas protects colon cancer cells from cucurbitacin-induced apoptosis: the role of p53 and p21.

Authors:  José M Escandell; Pawan Kaler; M Carmen Recio; Takehiko Sasazuki; Senji Shirasawa; Leonard Augenlicht; José-Luis Ríos; Lidija Klampfer
Journal:  Biochem Pharmacol       Date:  2008-05-08       Impact factor: 5.858

8.  Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa.

Authors:  M T de Bruijn; D A E Raats; F J H Hoogwater; W J van Houdt; K Cameron; J P Medema; I H M Borel Rinkes; O Kranenburg
Journal:  Br J Cancer       Date:  2010-03-30       Impact factor: 7.640

9.  Non-coding MicroRNAs hsa-let-7g and hsa-miR-181b are Associated with Chemoresponse to S-1 in Colon Cancer.

Authors:  Go Nakajima; Kazuhiko Hayashi; Yaguang Xi; Kenji Kudo; Kazumi Uchida; Ken Takasaki; Masakazu Yamamoto; Jingfang Ju
Journal:  Cancer Genomics Proteomics       Date:  2006-10       Impact factor: 4.069

10.  Macrophage-derived IL-1beta stimulates Wnt signaling and growth of colon cancer cells: a crosstalk interrupted by vitamin D3.

Authors:  P Kaler; L Augenlicht; L Klampfer
Journal:  Oncogene       Date:  2009-08-24       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.